Biotech entity
Of the tracked stories, 1 of 2 also mention 2024-2025 COVID-19 Vaccine, the most common co-covered peer. Across a 103-day span, the pace is roughly 0.1 stories per week. The 6.5 average consequence score is above the beat benchmark of 6.3 in the same window.
Last mentioned: Jun 28, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 1 of 2 also mention 2024-2025 COVID-19 Vaccine, the most common co-covered peer. Across a 103-day span, the pace is roughly 0.1 stories per week. The 6.5 average consequence score is above the beat benchmark of 6.3 in the same window. Coverage clusters in clinical-trial, which accounts for 1 of those 2, with the remainder spread across 1 other category. Each story carries 3 original sources on average, compared with 3.1 for the broader beat in this window. U.S. Department of Veterans Affairs appears in 2 tracked Biotech stories published from March 18, 2026 through June 28, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 178 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering U.S. Department of Veterans Affairs. Shared-story counts are live from our verified record — not editorial picks.
Expansion Target
Goal to reach 130 active sales territories by fiscal year-end
Earnings Release
Announced 63% revenue growth and VA hospital network access
Q3 Fiscal End
Closed third quarter with 100 active sales territories
Equity Offering
Completed capital raise to bolster cash position to $291M
The 2024-2025 COVID vaccine reduced MACE by 37.7% in a large VA trial, with even greater benefits in high-risk subgroups, sparking biopharma interest in a cardiovascular indication for mRNA vaccines.
Source: wtag.iheart.com · wrno.iheart.com
Kestra Medical reported a 63% year-over-year revenue increase to $24.6 million in Q3 2026, driven by record prescriptions for its Assure wearable cardioverter defibrillator. The company significantly expanded its market access through a new U.S. Department of Veterans Affairs contract and improved Medicaid coverage in Florida.
U.S. Department of Veterans Affairs is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
